Search research articles
Contact Us
Filters
Showing results (201-210 of 206) with videos related to
Page
of 21
Sort By:
You have reached the last page of results.
This site can display upto 206 results.
ESMO Open
|
February 13, 2024
Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer-final results of the EUCROSS trial
S Michels, B Massutí, I Vasyliv, et al.
Cancer Medicine
|
May 22, 2020
Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessment
Lucia Nogova, Christian Mattonet, Matthias Scheffler, et al.
Nature Communications
|
November 9, 2018
Overcoming EGFR<sup>G724S</sup>-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors
Jana Fassunke, Fabienne Müller, Marina Keul, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 13, 2019
Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial
Sebastian Michels, Bartomeu Massutí, Hans-Ulrich Schildhaus, et al.
Nature
|
March 14, 2024
Evolutionary trajectories of small cell lung cancer under therapy
Julie George, Lukas Maas, Nima Abedpour, et al.
BMJ Open Sport & Exercise Medicine
|
August 3, 2023
Global Alliance for the Promotion of Physical Activity: the Hamburg Declaration
Jürgen M Steinacker, Willem van Mechelen, Wilhelm Bloch, et al.
Page
of 21
Search research articles
Search
Showing results (201-210 of 206) with videos related to
Sort By:
Page
of 21
You have reached the last page of results.
This site can display upto 206 results.
ESMO Open
|
February 13, 2024
Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer-final results of the EUCROSS trial
S Michels, B Massutí, I Vasyliv, et al.
Cancer Medicine
|
May 22, 2020
Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessment
Lucia Nogova, Christian Mattonet, Matthias Scheffler, et al.
Nature Communications
|
November 9, 2018
Overcoming EGFR<sup>G724S</sup>-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors
Jana Fassunke, Fabienne Müller, Marina Keul, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 13, 2019
Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial
Sebastian Michels, Bartomeu Massutí, Hans-Ulrich Schildhaus, et al.
Nature
|
March 14, 2024
Evolutionary trajectories of small cell lung cancer under therapy
Julie George, Lukas Maas, Nima Abedpour, et al.
BMJ Open Sport & Exercise Medicine
|
August 3, 2023
Global Alliance for the Promotion of Physical Activity: the Hamburg Declaration
Jürgen M Steinacker, Willem van Mechelen, Wilhelm Bloch, et al.
Page
of 21